These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 24303093)

  • 1. Homogeneous phenomenon of the graft when using different genotype characteristic of recipients/donors in living donor liver transplantation.
    Chiu KW; Nakano T; Chen KD; Hsu LW; Lai CY; Chiu HC; Huang CY; Cheng YF; Goto S; Chen CL
    World J Hepatol; 2013 Nov; 5(11):642-8. PubMed ID: 24303093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pyrosequencing to identify homogeneous phenomenon when using recipients/donors with different CYP3A5*3 genotypes in living donor liver transplantation.
    Chiu KW; Nakano T; Chen KD; Lai CY; Hsu LW; Chiu HC; Huang CY; Cheng YF; Goto S; Chen CL
    PLoS One; 2013; 8(8):e71314. PubMed ID: 23951129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological interactions of CYP2C19 genotypes with CYP3A4*18, CYP3A5*3, and MDR1-3435 in living donor liver transplantation recipients.
    Chiu KW; Hu TH; Nakano T; Chen KD; Lai CY; Hsu LW; Tseng HP; Chiu HC; Cheng YF; Goto S; Chen CL
    Transplant Res; 2013 Apr; 2(1):6. PubMed ID: 23617933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation.
    Goto M; Masuda S; Kiuchi T; Ogura Y; Oike F; Okuda M; Tanaka K; Inui K
    Pharmacogenetics; 2004 Jul; 14(7):471-8. PubMed ID: 15226679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical relevance and prevalence of polymorphisms in CYP3A5 and MDR1 genes that encode tacrolimus biotransformation enzymes in liver transplant recipients.
    Barrera-Pulido L; Aguilera-García I; Docobo-Pérez F; Alamo-Martínez JM; Pareja-Ciuró F; Nuñez-Roldán A; Gómez-Bravo MA; Bernardos-Rodríguez A
    Transplant Proc; 2008 Nov; 40(9):2949-51. PubMed ID: 19010156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
    Fukudo M; Yano I; Yoshimura A; Masuda S; Uesugi M; Hosohata K; Katsura T; Ogura Y; Oike F; Takada Y; Uemoto S; Inui K
    Pharmacogenet Genomics; 2008 May; 18(5):413-23. PubMed ID: 18408564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytochrome P450 in living donor liver transplantation.
    Chiu KW; Nakano T; Chen KD; Hsu LW; Lai CY; Huang CY; Cheng YF; Goto S; Chen CL
    J Biomed Sci; 2015 May; 22(1):32. PubMed ID: 25975271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of IL-28B Genotype Modification in Hepatocytes after Living Donor Liver Transplantation by Laser Capture Microdissection and Pyrosequencing Analysis.
    Chiu KW; Nakano T; Chen KD; Hu TH; Lin CC; Hsu LW; Chen CL; Goto S
    Biomed Res Int; 2018; 2018():1826140. PubMed ID: 29686997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation.
    Goto M; Masuda S; Saito H; Uemoto S; Kiuchi T; Tanaka K; Inui K
    Pharmacogenetics; 2002 Aug; 12(6):451-7. PubMed ID: 12172213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients.
    Qiu XY; Jiao Z; Zhang M; Zhong LJ; Liang HQ; Ma CL; Zhang L; Zhong MK
    Eur J Clin Pharmacol; 2008 Nov; 64(11):1069-84. PubMed ID: 18636247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.
    Staatz CE; Goodman LK; Tett SE
    Clin Pharmacokinet; 2010 Mar; 49(3):141-75. PubMed ID: 20170205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Personalizing initial calcineurin inhibitor dosing by adjusting to donor CYP3A-status in liver transplant patients.
    Monostory K; Tóth K; Kiss Á; Háfra E; Csikány N; Paulik J; Sárváry E; Kóbori L
    Br J Clin Pharmacol; 2015 Dec; 80(6):1429-37. PubMed ID: 26271661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combinational effect of intestinal and hepatic CYP3A5 genotypes on tacrolimus pharmacokinetics in recipients of living donor liver transplantation.
    Ji E; Choi L; Suh KS; Cho JY; Han N; Oh JM
    Transplantation; 2012 Oct; 94(8):866-72. PubMed ID: 22992768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients.
    Kuypers DR; de Jonge H; Naesens M; Lerut E; Verbeke K; Vanrenterghem Y
    Clin Pharmacol Ther; 2007 Dec; 82(6):711-25. PubMed ID: 17495880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients.
    Fukudo M; Yano I; Masuda S; Goto M; Uesugi M; Katsura T; Ogura Y; Oike F; Takada Y; Egawa H; Uemoto S; Inui K
    Clin Pharmacol Ther; 2006 Oct; 80(4):331-45. PubMed ID: 17015051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver Transplant Patient Carriers of Polymorphism Cyp3a5*1 Donors May Need More Doses of Tacrolimus From the First Month After Transplantation.
    Argudo A; González de Aledo JM; Alía P; Ramírez P; Serrano T; Fabregat J; Castellote J
    Transplant Proc; 2015 Oct; 47(8):2388-92. PubMed ID: 26518936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Influence of CYP3A5 Gene Polymorphism on Pharmacokinetics of Tacrolimus and Patient Outcome After Living Donor Liver Transplantation.
    Kato H; Usui M; Muraki Y; Tanemura A; Murata Y; Kuriyama N; Azumi Y; Kishiwada M; Mizuno S; Sakurai H; Okuda M; Nakatani K; Isaji S
    Transplant Proc; 2016 May; 48(4):1087-94. PubMed ID: 27320564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interactive effects of CYP3A4, CYP3A5, MDR1 and NR1I2 polymorphisms on tracrolimus trough concentrations in early postrenal transplant recipients.
    Li JL; Liu S; Fu Q; Zhang Y; Wang XD; Liu XM; Liu LS; Wang CX; Huang M
    Pharmacogenomics; 2015; 16(12):1355-65. PubMed ID: 26228923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Donor and recipient P450 gene polymorphisms influence individual pharmacological effects of tacrolimus in Chinese liver transplantation patients.
    Liu J; Ouyang Y; Chen D; Yao B; Lin D; Li Z; Zang Y; Liu H; Fu X
    Int Immunopharmacol; 2018 Apr; 57():18-24. PubMed ID: 29454235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
    Staatz CE; Goodman LK; Tett SE
    Clin Pharmacokinet; 2010 Apr; 49(4):207-21. PubMed ID: 20214406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.